{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:30:24Z","timestamp":1790037024838,"version":"4.0.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["285223"],"award-info":[{"award-number":["285223"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004012","name":"Jane and Aatos Erkko Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Juselius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005633","name":"Finnish Foundation for Cardiovascular Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013500","name":"Finnish Diabetes Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013500","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Liv och H\u00e4lsa Foundation"},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"crossref","award":["NNF17OC0027234"],"award-info":[{"award-number":["NNF17OC0027234"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008484","name":"Paavo Nurmi Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004155","name":"Magnus Ehrnrooth Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.atherosclerosis.2018.03.019","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T18:14:30Z","timestamp":1520532870000},"page":"27-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?"],"prefix":"10.1016","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5553-7997","authenticated-orcid":false,"given":"Vesa M.","family":"Olkkonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Sinisalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Jauhiainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/VHRM.S104369","article-title":"Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease","volume":"12","author":"Toth","year":"2016","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrcardio.2015.92","article-title":"Management of patients with familial hypercholesterolaemia","volume":"12","author":"Reiner","year":"2015","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib4","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1161\/01.ATV.17.4.715","article-title":"The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial","volume":"17","author":"Alaupovic","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib5","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0022-2275(20)38428-5","article-title":"Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits","volume":"29","author":"Nordestgaard","year":"1988","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib6","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.ATV.14.11.1767","article-title":"Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque","volume":"14","author":"Rapp","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib7","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/S0021-9258(19)85958-6","article-title":"Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins","volume":"255","author":"Goldstein","year":"1980","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A\u00a0meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/MOL.0000000000000456","article-title":"New approaches to address dyslipidemia","volume":"28","author":"Parhofer","year":"2017","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib10","first-page":"1","article-title":"Changes in the leading cause of death: recent patterns in heart disease and cancer mortality","author":"Heron","year":"2016","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1194\/jlr.R009720","article-title":"Genetic determinants of plasma triglycerides","volume":"52","author":"Johansen","year":"2011","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib12","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/nu5041218","article-title":"Dyslipidemia in obesity: mechanisms and potential targets","volume":"5","author":"Klop","year":"2013","journal-title":"Nutrients"},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrendo.2017.119","article-title":"Angiopoietin-like 3 in lipoprotein metabolism","volume":"13","author":"Kersten","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib14","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-016-0614-1","article-title":"Why is apolipoprotein CIII emerging as a novel therapeutic target to reduce the burden of cardiovascular disease?","volume":"18","author":"Taskinen","year":"2016","journal-title":"Curr. Atherosclerosis Rep."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/ATVBAHA.115.306879","article-title":"Cholesteryl ester transfer protein inhibition is not yet dead\u2013pro","volume":"36","author":"Barter","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib16","doi-asserted-by":"crossref","DOI":"10.1007\/s11936-017-0549-z","article-title":"Lipoprotein(a): a lipoprotein whose time has come","volume":"19","author":"Kelly","year":"2017","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib17","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.bbalip.2011.10.010","article-title":"Regulation of triglyceride metabolism by Angiopoietin-like proteins","volume":"1821","author":"Mattijssen","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib18","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1194\/jlr.M075689","article-title":"ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance","volume":"58","author":"Haller","year":"2017","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib19","doi-asserted-by":"crossref","first-page":"19751","DOI":"10.1073\/pnas.1217552109","article-title":"Atypical angiopoietin-like protein that regulates ANGPTL3","volume":"109","author":"Quagliarini","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/01.ATV.0000252827.51626.89","article-title":"Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase","volume":"27","author":"Shimamura","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib21","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.bbrc.2004.03.151","article-title":"ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states","volume":"317","author":"Inukai","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib22","doi-asserted-by":"crossref","first-page":"E1299","DOI":"10.1210\/jc.2015-1254","article-title":"Regulation of angiopoietin-like proteins (ANGPTLs) 3 and 8 by insulin","volume":"100","author":"Nidhina Haridas","year":"2015","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib23","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2796.1991.tb00304.x","article-title":"A\u00a0form of familial hypobetalipoproteinaemia not due to a mutation in the apolipoprotein B gene","volume":"229","author":"Fazio","year":"1991","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/CIRCGENETICS.111.960674","article-title":"Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3","volume":"5","author":"Pisciotta","year":"2012","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib26","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cca.2011.11.020","article-title":"Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation","volume":"413","author":"Martin-Campos","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1161\/ATVBAHA.111.238766","article-title":"Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia","volume":"32","author":"Noto","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib28","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1194\/jlr.P066183","article-title":"Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism","volume":"57","author":"Minicocci","year":"2016","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib29","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/ATVBAHA.113.301397","article-title":"Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids","volume":"33","author":"Robciuc","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.atherosclerosis.2017.08.031","article-title":"Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol","volume":"268","author":"Xu","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib31","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20140115","article-title":"Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation","volume":"34","author":"Tikka","year":"2014","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib32","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib34","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MED.0000000000000136","article-title":"Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease","volume":"22","author":"Kohan","year":"2015","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib37","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20070308","article-title":"Apolipoprotein C-III: understanding an emerging cardiovascular risk factor","volume":"114","author":"Ooi","year":"2008","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/1871529X11202020133","article-title":"Human apolipoprotein C-III - a new intrahepatic protein factor promoting assembly and secretion of very low density lipoproteins","volume":"12","author":"Yao","year":"2012","journal-title":"Cardiovasc. Haematol. Disord. - Drug Targets"},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib39","doi-asserted-by":"crossref","first-page":"27769","DOI":"10.1074\/jbc.M110.203679","volume":"286","author":"Qin","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib40","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1194\/jlr.M005108","article-title":"Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia","volume":"51","author":"Sundaram","year":"2010","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib41","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jacl.2016.12.009","article-title":"Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions","volume":"11","author":"Mendoza","year":"2017","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib42","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.1038\/s41598-017-07821-5","article-title":"Dysfunctional high-density lipoproteins have distinct composition, diminished anti-inflammatory potential and discriminate acute coronary syndrome from stable coronary artery disease patients","volume":"7","author":"Carnuta","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib43","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/CIRCULATIONAHA.105.591743","article-title":"Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells","volume":"113","author":"Kawakami","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/01.ATV.0000249620.68705.0d","article-title":"Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation","volume":"27","author":"Kawakami","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib45","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-016-0745-6","article-title":"Triglyceride-rich lipoproteins and remnants: targets for therapy?","volume":"18","author":"Dallinga-Thie","year":"2016","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib46","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tips.2015.07.001","article-title":"Apolipoprotein C-III: from pathophysiology to pharmacology","volume":"36","author":"Norata","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib47","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib48","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib49","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1161\/01.ATV.0000066131.01313.EB","article-title":"LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients","volume":"23","author":"Lee","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib50","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0022-2275(20)37594-5","article-title":"Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur 'Infarctus du Myocarde","volume":"37","author":"Luc","year":"1996","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib51","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1161\/01.CIR.102.16.1886","article-title":"VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial","volume":"102","author":"Sacks","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib52","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1373\/clinchem.2008.103234","article-title":"Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn sstudy","volume":"54","author":"Scheffer","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib53","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1161\/ATVBAHA.115.305415","article-title":"Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics","volume":"35","author":"Qamar","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib54","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.mol.0000162320.54795.68","article-title":"The APOA1\/C3\/A4\/A5 gene cluster, lipid metabolism and cardiovascular disease risk","volume":"16","author":"Lai","year":"2005","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib55","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"Jorgensen","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib56","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A\u00a0null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Tg, Hdl Working Group of the Exome Sequencing Project NHL","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib58","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacl.2015.05.002","article-title":"The risk of cardiovascular events with increased apolipoprotein CIII: a systematic review and meta-analysis","volume":"9","author":"Wyler von Ballmoos","year":"2015","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib59","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature22034","article-title":"Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity","volume":"544","author":"Saleheen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib60","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.2337\/diacare.27.6.1358","article-title":"Diabetes Atorvastatin lipid intervention study G. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides","volume":"27","author":"Dallinga-Thie","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib61","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1185\/03007995.2010.509264","article-title":"Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters","volume":"26","author":"Karalis","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib62","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib63","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib64","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib65","article-title":"Apoc-III antisense oligonucleotides: a new option for the treatment of hypertriglyceridemia","author":"Schmitz","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.03.019_bib66","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8960236","article-title":"The impact of CRISPR\/Cas9 technology on cardiac research: from disease modelling to therapeutic approaches","author":"Motta","year":"2017","journal-title":"Stem Cell. Int."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018301333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018301333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T10:51:06Z","timestamp":1655981466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018301333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":66,"alternative-id":["S0021915018301333"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.03.019","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}